Joanne Xiu, Vice President, Clinical and Translational Research at Caris Life Sciences, shared a post on LinkedIn:
“Through systematic interrogation of biomarkers across the mechanism of action in a large real-world clinico-genomic dataset from Caris Life Sciences, ABCC1-mediated drug efflux was identified as a key driver of resistance to trastuzumab deruxtecan, a transformative antibody-drug conjugate.”
Title: Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling
Authors: George Sledge, Joanne Xiu, Reshma Mahtani, Ana Sandoval Leon, Funda Meric-Bernstam, Jennifer Ribeiro, Ninad Kulkarni, Dileep Rampa, Jangsoon Lee, Naoto Ueno, Matthew Oberley, Milan Radovich, David Spetzler
Read the Full Article.
More from Joanne Xiu.